Literature DB >> 21383092

Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy.

Jean Longtin1, Christie Vermeiren, Dea Shahinas, Gurdip Singh Tamber, Allison McGeer, Donald E Low, Kevin Katz, Dylan R Pillai.   

Abstract

Penicillin nonsusceptibility has been demonstrated in group B streptococci (GBS), but there is limited information regarding mechanisms of resistance. We report a case of GBS with reduced susceptibility to penicillin emerging after long-term suppressive oral penicillin therapy for a prosthetic joint infection. Molecular characterization of the isolate before and after long-term penicillin therapy revealed 5 mutations in the ligand-binding regions of PBP1a, -2a, and -2x not previously reported in GBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383092      PMCID: PMC3101384          DOI: 10.1128/AAC.01243-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  DaliLite workbench for protein structure comparison.

Authors:  L Holm; J Park
Journal:  Bioinformatics       Date:  2000-06       Impact factor: 6.937

2.  BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors:  G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone.

Authors:  Christiane Gaudreau; René Lecours; Johanne Ismaïl; Simon Gagnon; Louise Jetté; Michel Roger
Journal:  J Antimicrob Chemother       Date:  2009-12-18       Impact factor: 5.790

4.  Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci.

Authors:  C Betriu; M Gomez; A Sanchez; A Cruceyra; J Romero; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 5.  beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins.

Authors:  R Hakenbeck; T Grebe; D Zähner; J B Stock
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

6.  Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.

Authors:  J C de Azavedo; M McGavin; C Duncan; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance.

Authors:  Amanda L Jones; Rachel H V Needham; Anne Clancy; Katherine M Knoll; Craig E Rubens
Journal:  Mol Microbiol       Date:  2003-01       Impact factor: 3.501

8.  Penicillin-binding protein gene alterations in Streptococcus uberis isolates presenting decreased susceptibility to penicillin.

Authors:  Marisa Haenni; Laure Galofaro; Mathilde Ythier; Marlyse Giddey; Paul Majcherczyk; Philippe Moreillon; Jean-Yves Madec
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

9.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.

Authors:  Stephanie Schrag; Rachel Gorwitz; Kristi Fultz-Butts; Anne Schuchat
Journal:  MMWR Recomm Rep       Date:  2002-08-16

10.  mlstdbNet - distributed multi-locus sequence typing (MLST) databases.

Authors:  Keith A Jolley; Man-Suen Chan; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2004-07-01       Impact factor: 3.169

View more
  27 in total

1.  Changing Epidemiology of Group B Streptococcus Susceptibility to Fluoroquinolones and Aminoglycosides in France.

Authors:  Constantin Hays; Mathilde Louis; Céline Plainvert; Nicolas Dmytruk; Gérald Touak; Patrick Trieu-Cuot; Claire Poyart; Asmaa Tazi
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Antimicrobial susceptibilities of group B streptococcus isolates from prenatal screening samples.

Authors:  Benjamin R Berg; Jeana L Houseman; Zachary E terSteeg; William D LeBar; Duane W Newton
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

3.  Characterization of multidrug-resistant group B streptococci with reduced penicillin susceptibility forming small non-Beta-hemolytic colonies on sheep blood agar plates.

Authors:  Hirotsugu Banno; Kouji Kimura; Yosuke Tanaka; Hiromitsu Kitanaka; Wanchun Jin; Jun-ichi Wachino; Keiko Yamada; Keigo Shibayama; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

4.  A Single Amino Acid Replacement in Penicillin-Binding Protein 2X in Streptococcus pyogenes Significantly Increases Fitness on Subtherapeutic Benzylpenicillin Treatment in a Mouse Model of Necrotizing Myositis.

Authors:  Randall J Olsen; Luchang Zhu; James M Musser
Journal:  Am J Pathol       Date:  2020-05-11       Impact factor: 4.307

5.  Penicillin-susceptible group B streptococcal clinical isolates with reduced cephalosporin susceptibility.

Authors:  Noriyuki Nagano; Yukiko Nagano; Masami Toyama; Kouji Kimura; Keigo Shibayama; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

6.  Reduced In Vitro Susceptibility of Streptococcus pyogenes to β-Lactam Antibiotics Associated with Mutations in the pbp2x Gene Is Geographically Widespread.

Authors:  James M Musser; Stephen B Beres; Luchang Zhu; Randall J Olsen; Jaana Vuopio; Hanne-Leena Hyyryläinen; Kirsi Gröndahl-Yli-Hannuksela; Karl G Kristinsson; Jessica Darenberg; Birgitta Henriques-Normark; Steen Hoffmann; Dominque A Caugant; Andrew J Smith; Diane S J Lindsay; David M Boragine; Timothy Palzkill
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

7.  Molecular Characteristics of Group B Streptococci Isolated from Adults with Invasive Infections in Japan.

Authors:  Miyuki Morozumi; Takeaki Wajima; Misako Takata; Satoshi Iwata; Kimiko Ubukata
Journal:  J Clin Microbiol       Date:  2016-08-24       Impact factor: 5.948

8.  A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.

Authors:  Sharon L Hillier; Patricia Ferrieri; Morven S Edwards; Marian Ewell; Daron Ferris; Paul Fine; Vincent Carey; Leslie Meyn; Dakota Hoagland; Dennis L Kasper; Lawrence C Paoletti; Heather Hill; Carol J Baker
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

9.  Streptococcus agalactiae infection in cancer patients: a five-year study.

Authors:  B A S Pimentel; C A S Martins; J C Mendonça; P S D Miranda; G F Sanches; A L Mattos-Guaraldi; P E Nagao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-18       Impact factor: 3.267

10.  High isolation rate and multidrug resistance tendency of penicillin-susceptible group B Streptococcus with reduced ceftibuten susceptibility in Japan.

Authors:  Hirotsugu Banno; Kouji Kimura; Tomomi Seki; Wanchun Jin; Jun-Ichi Wachino; Keiko Yamada; Noriyuki Nagano; Yoshichika Arakawa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-17       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.